Market Place
Sourcing Support
Cantex Pharma: Four Azeliragon Abstracts At ASCO 2024 Annual Meeting
28 May 2024 //
PR NEWSWIRE
CANTEX Gets FDA Orphan Drug For Azeliragon In Pancreatic Cancer
20 May 2024 //
PR NEWSWIRE
CANTEX TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
19 Mar 2024 //
PR NEWSWIRE
Cantex & Michigan Announce Initiation Of Phase 3 Trial To Evaluate Azeliragon
27 Sep 2023 //
PR NEWSWIRE
Cantex and Allegheny Health Announce Initiation of a Phase 1/2 of Azeliragon
26 Sep 2023 //
PR NEWSWIRE
Cantex & Lenox Hill Hospital Announce Initiation of Phase 2 Study of Azeliragon
18 Sep 2023 //
PR NEWSWIRE
Cantex Announces Initiation of Invg-Initiated Ph2 Trial Investigating Azeliragon
28 Aug 2023 //
PR NEWSWIRE
Cantex Announces Article Published in npj Highlighting Role of RAGE Inhibition
10 Aug 2023 //
PR NEWSWIRE
Cantex To Present At The Medinvest Oncology Investor Conference In Boston
15 Jun 2023 //
PR NEWSWIRE
Cantex Obtains Exclusive Worldwide Rights To Intellectual Property
01 Jun 2023 //
PR NEWSWIRE
Cantex Pharma Announces Issuance Of A Patent For Azeliragon
16 May 2023 //
PR NEWSWIRE
Cantex & Michigan Medicine Announce Initiation Ph 2/3 Clinical Study Azeliragon
20 Apr 2023 //
PR NEWSWIRE
Cantex Receives FDA Orphan Drug Designation for Azeliragon for Glioblastoma
09 Jan 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.